{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:50:33Z","timestamp":1790686233302,"version":"4.1.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T00:00:00Z","timestamp":1528675200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13045-018-0626-0","type":"journal-article","created":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T08:53:04Z","timestamp":1528707184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4687-7089","authenticated-orcid":false,"given":"Gianluigi","family":"Reda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fattizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Cassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mattiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Tonella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Cortelezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,11]]},"reference":[{"key":"626_CR1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/asheducation-2017.1.346","volume":"2017","author":"MS Davids","year":"2017","unstructured":"Davids MS. How should we sequence and combine novel therapies in CLL? Hematology Am Soc Hematol Educ Program. 2017;2017:346\u201353.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"626_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40265-017-0695-3","volume":"77","author":"ED Deeks","year":"2017","unstructured":"Deeks ED. Ibrutinib: a review in chronic lymphocytic Leukaemia. Drugs. 2017;77:225\u201336.","journal-title":"Drugs"},{"key":"626_CR3","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","volume":"1","author":"TE Wiczer","year":"2017","unstructured":"Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, Rogers K, McCoy A, Mousa L, Guha A, Heerema NA, Maddocks K, Christian B, Andritsos LA, Jaglowski S, Devine S, Baiocchi R, Woyach J, Jones J, Grever M, Blum KA, Byrd JC, Awan FT. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017;1:1739\u201348.","journal-title":"Blood Adv"},{"key":"626_CR4","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","volume":"124","author":"JR McMullen","year":"2014","unstructured":"McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124:3829\u201330.","journal-title":"Blood"},{"key":"626_CR5","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/bjh.14324","volume":"175","author":"PA Thompson","year":"2016","unstructured":"Thompson PA, L\u00e9vy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, Ysebaert L, Michallet AS, Dilhuydy MS, Van Den Neste E, Dupuis J, Keating MJ, Meune C, Cymbalista F. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol. 2016;175:462\u20136.","journal-title":"Br J Haematol"},{"key":"626_CR6","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3324\/haematol.2017.171041","volume":"102","author":"JR Brown","year":"2017","unstructured":"Brown JR, Moslehi J, O\u2019Brien S, Ghia P, Hijlmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102:462\u20136.","journal-title":"Haematologica"},{"key":"626_CR7","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","volume":"58","author":"TD Shanafelt","year":"2017","unstructured":"Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J, Call TG, Schwager SM, Ding W, Eichhorst B, Fischer K, Leis JF, Chanan-Khan AA, Hallek M, Slager SL, Kay NE. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017;58:1630\u20139.","journal-title":"Leuk Lymphoma"},{"key":"626_CR8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0140-6736(09)60443-8","volume":"373","author":"RB Schnabel","year":"2009","unstructured":"Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB Sr, Newton-Cheh C, Yamamoto JF, Magnani JW, Tadros TM, Kannel WB, Wang TJ, Ellinor PT, Wolf PA, Vasan RS, Benjamin EJ. Development of a risk score for atrial fibrillation (Framingham heart study): a community-based cohort study. Lancet. 2009;373:739\u201345.","journal-title":"Lancet"},{"key":"626_CR9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","volume":"128","author":"DP Leong","year":"2016","unstructured":"Leong DP, Caron F, Hillis C, Duan A, Healey JS, Fraser G, Siegal D. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128:138\u201340.","journal-title":"Blood"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0626-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-018-0626-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0626-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T04:47:21Z","timestamp":1571460441000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-018-0626-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,11]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["626"],"URL":"https:\/\/doi.org\/10.1186\/s13045-018-0626-0","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,11]]},"assertion":[{"value":"3 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The data collection on CLL patients had been approved by the local Ethical Committee and patients gave informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"79"}}